OBJECTIVE. It is still controversial whether sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) are equally effective in patients with diabetes mellitus. In these patients, multiple individual variables may be responsible for neointimal hyperplasia, thus making difficult the comparison of the two drug-eluting stents (DES).
INTRODUCTION
Diabetes mellitus is an important risk factor for poor outcomes after elective percutaneous coronary intervention (PCI) (1) . In particular, diabetic patients are prone to a diffuse and rapidly progressive form of atherosclerosis, which increases their likelihood of requiring revascularization (1) . Several randomized trials and meta-analyses have shown that both sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) markedly reduce restenosis rates and the need for repeated revascularization procedures compared with bare-metal stents in patients with diabetes mellitus (2-7). However, it is still controversial whether SES and PES are equally effective in the prevention of restenosis in these patients. A recent prospective randomized trial demonstrated that the use of SES is associated with a reduced risk of restenosis, as compared with PES in diabetic patients (8) . On the other hand, recent meta-analyses (9,10), retrospective studies (11, 12) and a large registry (13) revealed no difference between these two drug-eluting stents (DES) in terms of restenosis and target lesion revascularization. Notably, in diabetic patients, multiple individual variables, including systemic inflammatory status, glycemic control over the time, insulin plasma levels, prothrombotic state, type of and response to medical treatment, may be responsible for neointimal hyperplasia after coronary stenting (14), thus making difficult the comparison of the two DES in different patient groups. We therefore designed a prospective, randomized, multicenter, not-sponsored study to directly compare the efficacy in the prevention of restenosis of SES and PES, both implanted in the same diabetic patient in order to obviate for the multiple and unpredictable characteristics of this high-risk population. Patients were considered eligible if they presented diabetes mellitus, angina pectoris and/or a positive stress test, the presence of at least two significant angiographic stenoses in different native coronary vessels or in the same vessel but two different coronary segments. Patients were jointly evaluated in each institution by a cardiovascular team, composed by a cardiac surgeon, an interventional cardiologist and a clinician. The final decision of patient enrolment was made after comprehensive review of all relevant factors. To be enrolled into the study, patients had to be considered suitable for PCI by the cardiovascular team. The diagnosis of diabetes mellitus was confirmed in all patients receiving active treatment with an oral hypoglycemic agent or insulin; for patients with a diagnosis of diabetes who were receiving dietary therapy alone, enrolment in the trial required the documentation of an abnormal blood glucose level after an overnight fast or an abnormal glucose-tolerance test. Exclusion criteria included ST-segmentelevation myocardial infarction, a target lesion in the left main trunk or coronary artery bypass graft, in-stent restenosis, patients with ≥2 lesions in the same coronary segment unsuitable to be treated with one DES, any contraindication to the use of aspirin, heparin, and/or clopidogrel, and lack of consent to participate in the study. The study protocol was approved by the institutional ethics committees at all participating centers. All patients provided written informed consent prior to catheterisation for participation in the study.
RESEARCH DESIGN AND METHODS
envelopes containing a computer-generated randomization sequence for coronary vessel (left anterior descending or left circumflex or right coronary artery). In patients with multivessel disease and more than 1 lesion in the same vessel but different coronary segments, the assigned DES was implanted in the more proximal lesion. For enrolled patients with single vessel disease and ≥2 significant stenoses in different coronary segments, a second envelope containing a computergenerated randomization sequence for coronary segment (proximal or mid-distal portion of the vessel) was used. For patients with multivessel disease requiring implantation of more than two stents, the type of stent implanted in the remaining lesions (or vessels) was left to operator' discretion and was excluded from the angiographic analysis. The implantation of multiple overlapping coronary DES was allowed in case of incomplete lesion coverage, and/or endoluminal injury requiring additional stent coverage beyond the margins of the initial stent deployed. Periprocedural antithrombotic therapy consisted of aspirin and heparin at standard dosages and clopidogrel at a loading dose of 300 mg. Platelet glycoprotein IIb/IIIa inhibitors were given only to patients with acute coronary syndromes. After the intervention, the protocol mandated the use of antiplatelet therapy consisting of 100 mg/day of aspirin indefinitely as well as 75 mg/day of clopidogrel for at least six months. All patients were asked to return for coronary angiography at 8 months after the procedure, or earlier if symptoms occurred. Relevant data were collected and entered into a computerized database by specialized personnel at the clinical data-management center (European Hospital, Rome, Italy). All data were verified with the use of hospital records or the records of family physicians.
Quantitative Coronary Angiography (QCA)
Baseline, post-procedural, and follow-up coronary angiograms were digitally recorded and assessed off-line in a quantitative angiographic core laboratory (Rome Heart Research, Rome, Italy) with an automated edge-detection system CMS (Medis Medical Imaging Systems) (15) by experienced personnel unaware of the study protocol. All measurements were performed on cineangiograms recorded after the intracoronary administration of nitroglycerin. The contrast-filled nontapered catheter tip was used for calibration. The reference diameter was determined by interpolation. The variables that were measured included the reference diameter of the vessel, the minimal luminal diameter (MLD), the extent of stenosis (the difference between the reference diameter and the MLD, divided by the reference diameter and multiplied by 100), late luminal loss (LLL) (the difference between the MLD at the end of the procedure and the MLD at follow-up), and net luminal gain (the difference between the MLD at follow-up and the MLD before the procedure). Quantitative coronary analysis was used to evaluate the stented area ("in-stent") and the area that included the stented segment as well as the 5-mm margins proximal and distal to the stent ("in-segment"). We also evaluated the stent volume (postprocedural mean stent area of the stented segment X stent length), lumen volume (mean luminal area of the stented segment at follow-up X stent length), neointimal volume (stent volumelumen volume), and percentage neointimal obstruction (neointimal volume / stent volume X 100) as recently proposed by Tsuchida et al. (16) . The complexity of the lesions was defined according to the modified grading system of the American College of Cardiology-American Heart Association (17).
Study End Points
The primary end point of the study was in-stent LLL by QCA at 8-month follow-up angiography. We chose in-stent LLL as primary end point because it has been demonstrated to be a more reliable predictor of restenosis than in-segment LLL (18) . We also evaluated in-segment LLL, angiographic restenosis (defined as in-segment stenosis of at least 50 percent on follow-up angiography) and volumetric measurements at the time of angiographic follow-up.
Statistical Analysis
We calculated that a sample size of 55 patients, i.e., 110 lesions (55 per stent group), was needed for the detection of a difference between the two DES for in-stent LLL of 0.27±0.5 mm, with an 80% power and a twosided α error of 5%. This assumption was based on the results of the only available randomized head-to-head comparison trial with SES and PES in diabetic patients, which showed an in-stent LLL of 0.19±0.44 mm and of 0.46±0.64 mm, respectively (8) . Assuming a 10% dropout rate, we set a goal of 60 patients (120 lesions) for the study. Sample size was calculated with the use of Query Advisor (version 4.0, Statistical Solutions) according to the method of O'Brien and Muller. Comparisons of the continuous or discrete variables between stent groups were performed using a 2-tailed, unpaired t-test or a χ 2 test, respectively. To investigate the independent predictors of in-stent LLL, a multivariable regression analysis was performed in which all variables known to be relevant for the study end-point (type of DES, target vessel, lesion location, lesion type, vessel size, stent length, MLD before procedure, stenosis before procedure) were entered as independent variables. Data are expressed as mean ± SD, unless otherwise indicated. Values of P <0.05 were considered significant.
RESULTS
Out of 167 consecutive diabetic patients who met inclusion/exclusion criteria, 94 (56.3%) underwent surgical revascularization and 13 (7.8%) were treated with pharmacologic therapy, after joint evaluation of the cardiovascular team. The remaining 60 (35.9%) patients were enrolled in the study and randomly assigned to receive both a SES and a PES in different coronary lesions. Among a total of 146 coronary lesions in different coronary segments successfully treated with stent implantation, 120 received a randomly assigned DES (SES n=60 and PES n=60); the remaining 26 coronary lesions were treated with bare metal stents and not considered for angiographic analysis. Clinical characteristics, biochemical markers and pharmacological therapy at the time of enrolment of total population are summarized in Table 1 . Baseline angiographic characteristics of the lesions and procedural variables of patients treated with SES or PES are displayed in Table  2 .
Angiographic Results
Follow-up angiography at 8 months was performed in all 59 patients alive (1 patient died for SES thrombosis 18 days after the index intervention, as demonstrated at autopsy). The median duration of angiographic follow-up was 246 days (10th and 90th percentiles, 113 and 267). Table 3 shows the results of the quantitative analysis of follow-up angiograms. Both insegment and in-stent LLL were significantly lower in the SES group (0.41±0.6 vs 0.68±0.6 mm; P=0.04 and 0.26±0.4 vs 0.50±0.6 mm; P=0.01, respectively). Accordingly, the percentage of neointimal obstruction was significantly reduced in SES-treated lesions (10.2±15.5 vs 19.5±19.3%, P=0.005). Coronary lesions treated with SES presented a reduced in-stent LLL in 40 (68%) patients, while PES resulted in a lower in-stent LLL in 19 (32%) patients (P=0.0002). Figure 1 shows the cumulative rate of in-stent LLL at followup angiography. The rate of in-segment and in-stent restenosis and angiographic diameter stenosis were lower in the SES group, even if not statistically different. Target-lesion revascularization was performed by PCI on 5 (8.6%) coronary lesions treated with SES and 8 (13.8%) with PES (P=0.5). At the multivariable analysis, the type of DES implanted was the only independent predictor of in-stent LLL (OR 2.3; 95% CI 1.1-5.0; P=0.03).
CONCLUSIONS
This prospective, randomized, multicenter study demonstrates that in the same diabetic patient with multiple de novo coronary artery lesions, the use of SES is associated with a lower rate of LLL at 8 months, as compared with PES. Indeed, coronary lesions treated with SES presented a reduced in-stent LLL in the majority of patients. In-stent LLL reflects the degree of neointimal growth, which is the main cause of coronary restenosis. Indeed, there is a close relationship between in-stent LLL and the incidence of binary restenosis (18) , as well target vessel revascularization (19) , thus implying that the assessment of in-stent LLL can be regarded as an appropriate marker for assessing the efficacy of a DES (18, 19) . A well known limitation of LLL is that it represents only a surrogate for clinical end-points (18, 19) which, however, could not be taken into account in this study because both SES and PES were implanted in the same patient. Our data are in accordance with those of the recently published ISAR (In-Stent angiographic Restenosis)-DIABETES trial (8) that randomized 250 patients with diabetes to receive SES or PES. The PES was associated with a higher rate of in-segment LLL as well as an increased risk of angiographic restenosis, compared to SES. Our study was not sufficiently powered to assess the incidence of angiographic restenosis, even if there was a trend toward a lower incidence of restenosis in the SES group. Notably, the present study strengthens the main finding of the ISAR-DIABETES, since it demonstrates for the first time that the superiority of SES to PES is independent of all specific pathophysiological and clinical features of the diabetic population. Indeed, in these patients coronary restenosis resulting from neointimal hyperplasia (which causes LLL) is a very complex process, influenced by several pathophysiological mechanisms, including vascular inflammation, endothelial dysfunction, enhanced prothrombotic status, and insuline resistance (1). The role played by these mechanisms may also vary among different diabetic patients, but it is equalised in our clinical research model. Furthermore, a variety of individual features of the diabetic patient may influence the restenotic process, like glycemic control over the time, associated medical treatments and comorbidities, response to treatment, and associated risk factors (1) . Thus, all these variables, which may influence the restenotic process differently in each individual patient, may adversely affect any comparison between patient groups treated with different DES. However, the majority of these variables were not specifically taken into account in previous studies. The particular design of our study, in which both SES and PES were implanted in the same diabetic patient after randomization for coronary vessel and segment, permitted to adjust the obtained results for all these variables. Moreover, we found that the type of DES was the only independent predictor of in-stent LLL. Several factors may be responsible for the observed better angiographic performance of SES: a) a more profound inhibition of neointimal hyperplasia due to sirolimus, an immunosuppressive drug with antiinflammatory properties, b) a greater elution of the drug in a shorter time due to polymer coating of SES, and c) a more uniform distribution of the drug due to a closed-cell design of the BxVelocity stent.
The present study group represents onethird of the total diabetic population with multivessel disease who underwent coronary angiography during the study period. In fact, we preferred to enroll only patients deemed suitable for PCI by a joint evaluation of cardiac surgeon and interventional cardiologist. Nevertheless, surgical revascularization remains the recommended strategy for diabetic multivessel coronary artery disease (1) . Ongoing trials of PCI with DES versus CABG will provide more data on the best revascularization treatment in diabetic patients. In summary, this multicenter, randomized study demonstrates that SES, directly compared to PES in the same diabetic patient with multiple de novo coronary artery lesions, is associated with a decrease in the extent of instent LLL at 8 months, suggesting a reduced risk of restenosis. The better angiographic performance of SES does not necessarily translate into long-term clinical benefits. 
